Francois-Xavier Mahon

TL;DR: Imatinib mesylate was used to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene and observed grade 4 hematologic toxicity and a lack of response.

TL;DR: A new concept in the evaluation of CML entitled treatment-free remission will be the criterion to evaluate the success of future clinical trials, especially if the authors want to improve the management of the disease to the point where they can claim to have cured CML.

TL;DR: It is shown that whereas the pyrido[2,3-d] pyrimidines are indeed highly potent in suppressing proliferation of Bcr-Abl-overexpressing imatinib-resistant cells, they are almost completely ineffective against cells expressing the T315I mutant, which implies that despite structural differences from imatin ib, these drugs are unlikely to be useful in patients expressing this mutant Bcr -Abl protein.

TL;DR: Stopping TKI may be envisaged in pts with stable undetectable molecular residual disease (UMRD), as suggested by recent results from the STop IMatinib trial, and the observation that dasatinib could be safely stopped in a pt with a stable UMRD suffering from drug-induced pleural effusion.

TL;DR: It is confirmed that CMR can be sustained after discontinuation of imatinib with a long follow-up, particularly in male patients and in pts with cytotoxic NK cells in their peripheral blood.